Robert G. Shepler - 01 Jun 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: Director
Issuer ticker: AKYA
Reported as of: 01 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2022, 16:04:53 UTC
Prior SEC filing: 18 Nov 2021
Next SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert G. Shepler, by Brian McKelligon, as Attorney-in-Fact

Key filing fact

Robert G. Shepler filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 03 Jun 2022.

Key facts

This page summarizes Robert G. Shepler's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2022, 16:04.

Change

Previous filing in this sequence was filed on 18 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 249,592
Date: 01 Jun 2022
Ownership: Robert G. Shepler Separate Property Trust of 2008

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Stock Option (Right to Buy

Award

Transaction value: $0
Shares: +30,549
Change %
Price: $0.000000
Shares after: 30,549
Date: 01 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,549
Exercise price: $11.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.